$0.00
+0.00 (+0.00%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where WINT is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
14 interventional · 11 with posted results
Held by 0 tracked-famous managers · FINRA short interest 1.0 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| A Safety and Efficacy Trial of Istaroxime for Cardiogenic Shock Stage CNCT05975021SBP AUC 0-6Randomized · Triple-masked · Treatment | Phase 1/2 | Active, not recruiting | Drug: Istaroxime, Placebo | Cardiogenic Shock | 20 | 2025-07-28actual | 2025-08-20 |
| The Safety and Efficacy of Istaroxime for Pre-Cardiogenic ShockNCT04325035Change from baseline in systolic blood pressure (SBP) area under the curve (AUC) 0-6Randomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: Istaroxime, Placebo | Cardiogenic Shock | 90 | 2024-09-26actual | 2025-02-04 |
| The Safety and Preliminary Tolerability of Lyophilized Lucinactant in Adults With Coronavirus Disease 2019 (COVID-19)NCT04389671results2023-06-23Oxygen Index (OI)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ · Informed Consent Form ↗ | Phase 2 | Completed | Drug: Lucinactant | COVID-19, Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS) | 20 | 2022-02-20actual | 2023-06-23 |
| A Safety and Efficacy Study of Lucinactant for Inhalation in Preterm Neonates 26 to 32 Weeks Gestational AgeNCT04264156results2023-05-24Number of Participants With Respiratory Failure or DeathRandomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ · Informed Consent Form ↗ | Phase 2 | Terminatedsponsor's stated reason: Corporate business reasons | Combination product: Lucinactant for Inhalation · Other: nCPAP Only | Respiratory Distress Syndrome, Newborn | 12 | 2021-01-31actual | 2023-05-24 |
| The Clinical Study of the Safety and Efficacy of Istaroxime in Treatment of Acute Decompensated Heart FailureNCT02617446results2023-05-24Change in E/Ea RatioRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ · Informed Consent Form ↗ | Phase 2 | Completed | Drug: Placebo, Istaroxime | Acute Decompensated Heart Failure | 120 | 2018-08-14actual | 2023-05-24 |
| Antihypertensive Effect of Different Doses of Rostafuroxin in Comparison With LosartanNCT03217825Systolic Blood PressureRandomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: Rostafuroxin, Losartan | Hypertension | 240 | 2018-02-08actual | 2023-02-21 |
| The Safety and Efficacy of Lucinactant for Inhalation in Premature Neonates 26 to 32 Weeks Gestational AgeNCT02636868results2021-04-23Number of Participants With Respiratory Failure or Death Due to Respiratory Distress Syndrome (RDS)Randomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ · Informed Consent Form ↗ | Phase 2 | Completed | Drug: Lucinactant delivered via investigational delivery device, nCPAP | Respiratory Distress Syndrome | 221 | Jul 2017actual | 2021-04-23 |
| Trial To Assess The Safety And Tolerability Of Lucinactant For Inhalation In Preterm Neonates 26 to 28 Weeks PMANCT02528318results2019-07-23Number of Participants With Peri-Dosing Adverse Events - Initial DoseRandomized · Open-label · TreatmentStatistical Analysis Plan ↗ · Study Protocol ↗ | Phase 2 | Terminatedsponsor's stated reason: Sponsor decision to terminate after 3 dosing groups | Combination product: Lucinactant for inhalation · Device: nCPAP alone | Respiratory Distress Syndrome | 48 | 2017-05-31actual | 2019-07-23 |
| Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Premature NeonatesNCT02074059results2017-04-21Peri-Dosing EventsRandomized · Open-label · Treatment | Phase 2 | Completed | Drug: Lucinactant for Inhalation · Device: nCPAP alone | Respiratory Distress Syndrome | 80 | Oct 2015actual | 2017-04-21 |
| Lucinactant for Treatment of Acute Hypoxemic Respiratory Failure in Children up to Two Years OldNCT00578734results2012-04-27Duration of Mechanical Ventilation Through 14 DaysRandomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: Lucinactant · Other: Sham Comparator | Acute Hypoxemic Respiratory Failure | 165 | Apr 2010actual | 2012-05-03 |
| SURFAXIN® Treatment for Prevention of Bronchopulmonary Dysplasia (BPD) in Very Low Birth Weight (VLBW) Infants.NCT00215540results2012-06-13Incidence of Death or Bronchopulmonary Dysplasia (BPD) at 36 WeeksRandomized · Quadruple-masked · Prevention | Phase 2 | Terminatedsponsor's stated reason: Concerns related to availability of drug product | Drug: Lucinactant 175 mg/kg, Lucinactant 90 mg/kg, Placebo | Respiratory Distress Syndrome, Newborn, Premature Birth, Bronchopulmonary Dysplasia | 136 | Jul 2006actual | 2012-06-13 |
| KL₄Surfactant Treatment in Patients With ARDSNCT00215553results2012-04-27Incidence of Patients Being Alive and Not Receiving Mechanical Ventilation for ≥48 Hours at the End of Day 28.Randomized · Open-label · Treatment | Phase 2 | Terminatedsponsor's stated reason: Slow enrollment and administrative reasons | Drug: A.1 Lucinactant, A.2 Lucinactant, A.3 Lucinactant, A.4 Lucinactant, B.1 Lucinactant, B.2 Lucinactant · Other: B.3 SoC | Acute Respiratory Distress Syndrome | 124 | Feb 2006actual | 2018-08-09 |
| Feasibility Study of Aerosolized Surfaxin in the Prevention of Respiratory Distress Syndrome (RDS) in Premature InfantsNCT00807235results2012-06-13Number of Participants With Respiratory Distress SyndromeNon-randomized · Open-label · Prevention | Phase 2 | Terminatedsponsor's stated reason: Slow enrollment | Drug: Aerosolized lucinactant, Aerosolized lucinactant | Respiratory Distress Syndrome | 17 | Aug 2005actual | 2012-06-13 |
| Phase III Randomized Study of Lucinactant in Full Term Newborn Infants With Meconium Aspiration SyndromeNCT00004500results2012-05-01Number of Days Receiving Mechanical Ventilation (MV)Randomized · Open-label · Treatment | Phase 3 | Terminatedsponsor's stated reason: Slow enrollment and administrative reasons | Drug: Lucinactant · Other: Standard Care | Meconium Aspiration | 69 | Nov 2002actual | 2012-05-03 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19